

G3  
cancel

- 3 -

(b) binding said HLA-B7 molecule and said peptide.

201. (Once Amended) The method of claim 177, wherein said epitope is selected from the group consisting of: LPENNVLSPL (SEQ ID NO:13), APAPAPSWPL (SEQ ID NO:14), SPALNKMFCQL (SEQ ID NO:15), RPILTIITL (SEQ ID NO:17), LPPGSTKRAL (SEQ ID NO:18), SPQPKKKPL (SEQ ID NO:19), and KPLDGEYFTL (SEQ ID NO:20).

~~202.~~ (Once amended) The method of claim 201, wherein said epitope is LPENNVLSPL (SEQ ID NO:13).

G1 \$

203. (Once amended) The method of claim 201, wherein said epitope is APAPAPSWPL (SEQ ID NO:14).

~~204.~~ (Once amended) The method of claim 201, wherein said epitope is SPALNKMFCQL (SEQ ID NO:15).

~~205.~~ (Once amended) The method of claim 201, wherein said epitope is RPILTIITL (SEQ ID NO:17).

~~206.~~ (Once amended) The method of claim 201, wherein said epitope is LPPGSTKRAL (SEQ ID NO:18).

~~207.~~ (Once amended) The method of claim 201, wherein said epitope is SPQPKKKPL (SEQ ID NO:19).

~~208.~~ (Once amended) The method of claim 201, wherein said epitope is KPLDGEYFTL  
(SEQ ID NO:20).

~~209.~~ (Once amended) A method of binding a human leukocyte antigen (HLA)-B7  
molecule with a peptide comprising an epitope of p53, comprising:

- G4  
cancel
- (a) contacting said HLA-B7 molecule with a peptide comprising an epitope selected  
from the group consisting of: GTRVRAMAI (SEQ ID NO:16) and GSRAHSSHL (SEQ  
ID NO:21); wherein said peptide is 8-11 amino acids in length; and thereby
  - (b) binding said HLA-B7 molecule and said peptide.

~~232.~~ (Once amended) The method of claim 209, wherein said epitope is GTRVRAMAI  
G5 (SEQ ID NO:16).

~~233.~~ (Once amended) The method of claim 209, wherein said epitope is GSRAHSSHL  
(SEQ ID NO:21).